ELEMENT
23.8.2022 06:02:17 CEST | Business Wire | Press release
Today at ACHEMA, Element , a leading provider of operations data management software to global industrials, announced a partnership with IPCOS , a global industrial digitalization solution provider, to bring increased efficiency and predictability to chemical plant customers through the Unify platform. Unify makes siloed, fragmented operations data useful for people to deliver expert analysis and guidance from anywhere, at any time.
“Through our close partnership with Element, IPCOS’ customers will gain access to the popular Unify platform closing the gap between MES and Cloud. With Unify, we can implement effective data management strategies integrating traditional data models developed at the MES layer with modern Cloud solutions. IPCOS believes this will be a significant accelerator for digitalization in the process industry, leading to increased effectiveness of their chemical processing operations,” said Filip Stroobant, Managing Director Digital Assets, IPCOS.
“We’re excited to partner with IPCOS to enable chemical operators who are racing to turn their exponentially growing operations data into a value-generating asset so their people can make faster decisions. Together, IPCOS and Element empower people with operations data to achieve analytical insights that improve on-stream time, resiliency, sustainability and profit,” said Andy Bane, CEO of Element.
Together, IPCOS and Element accelerate digital solutions that maximize the efficiency and sustainability of industrial plant operations. IPCOS’ deep knowledge of data-centric initiatives and ability to deliver greater value from industrial operations to their customers is further enhanced with the Unify operations data management platform, helping customers to reach their digital transformation initiatives faster, cheaper and at greater scale.
Element will be exhibiting at the ACHEMA Conference in Frankfurt, Germany August 22-26, 2022. Stop by the Element booth (Hall 11.0, Stand F54) to learn more about the company’s partnership with IPCOS and to receive a demonstration of the Unify platform, and/or read more in the Element blog post here .
About Element
Element is a leading software provider in operations data management. Element Unify empowers people with access to operations data to make faster decisions that deliver financial impact. Element’s customers represent over $750 billion in revenue, $500 billion in fixed assets and 450,000 employees. To learn more about Element, please visit elementanalytics.com
and follow the company on LinkedIn
and Twitter
.
About IPCOS
IPCOS is a services provider that maximizes the performance of its customers’ assets in the international chemical and energy industries. IPCOS experts implement tailor-made, state-of-the-art technology to increase plant operations efficiency and integrate information technologies into customer workflows to improve industrial processes. With an extensive track record, IPCOS is trusted to deliver unique engineering-based, technology-independent solutions that combine domain knowledge with technology know-how. For more information visit IPCOS.com
and follow the company on LinkedIn
and Twitter
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005705/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release
Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release
The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom